Wild-type (senile) ATTR amyloidosis surgery: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Wild-type (senile) ATTR amyloidosis}} | {{Wild-type (senile) ATTR amyloidosis}} | ||
{{CMG}} | {{CMG}} ; {{AE}} {{ADG}} | ||
==Overview== | ==Overview== | ||
Line 7: | Line 7: | ||
==Surgery== | ==Surgery== | ||
Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis. | Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis.<ref name="pmid31452023">{{cite journal |vauthors=Puig-Carrion GD, Reyentovich A, Katz SD |title=Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis |journal=Clin. Auton. Res. |volume=29 |issue=Suppl 1 |pages=45–53 |date=September 2019 |pmid=31452023 |pmc=6763576 |doi=10.1007/s10286-019-00629-5 |url=}}</ref> | ||
* Transplantation replaces the main source of variant TTR with a source of normal-sequence TTR. | * Transplantation replaces the main source of variant TTR with a source of normal-sequence TTR. |
Latest revision as of 07:09, 6 July 2020
Wild-type (senile) ATTR amyloidosis Microchapters |
Differentiating Wild-type (senile) ATTR amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) ATTR amyloidosis surgery On the Web |
American Roentgen Ray Society Images of Wild-type (senile) ATTR amyloidosis surgery |
Risk calculators and risk factors for Wild-type (senile) ATTR amyloidosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis.
Surgery
Liver transplantation is the mainstay of treatment for wild-type ATTR amyloidosis.[1]
- Transplantation replaces the main source of variant TTR with a source of normal-sequence TTR.
- This leads to gradual fibril reabsorption and disease stabilization, especially of neurologic complications.
References
- ↑ Puig-Carrion GD, Reyentovich A, Katz SD (September 2019). "Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis". Clin. Auton. Res. 29 (Suppl 1): 45–53. doi:10.1007/s10286-019-00629-5. PMC 6763576 Check
|pmc=
value (help). PMID 31452023.